false000172452100017245212025-01-162025-01-16

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________________________
FORM 8-K
________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 16, 2025
________________________________________________________
Arcus Biosciences, Inc.
(Exact name of Registrant as Specified in Its Charter)
________________________________________________________
Delaware001-3841947-3898435
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
3928 Point Eden Way
Hayward, California
94545
(Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: (510) 694-6200
(Former Name or Former Address, if Changed Since Last Report)
________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Common Stock, Par Value $0.0001 Per ShareRCUSThe New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 21, 2025, Arcus Biosciences, Inc. (the “Company”) announced that Richard Markus, M.D., Ph.D. has been appointed as the Company’s Chief Medical Officer, effective January 31, 2025, and that Dimitry Nuyten, M.D., Ph.D. will depart from the Company on January 31, 2025. Consistent with the terms of the Company’s Severance Benefits Plan, Dr. Nuyten entered into a customary separation agreement pursuant to which he is eligible to receive (i) a lump sum payment equal to twelve (12) months of his base salary, (ii) COBRA continuation coverage for up to 12-months and (iii) an additional cash payment in consideration of Dr. Nuyten’s 2024 annual bonus.
The foregoing description of the separation agreement does not purport to be complete, and is qualified in its entirety by reference to the final separation agreement, a copy of which will be filed with the Company’s public filings after execution.


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ARCUS BIOSCIENCES, INC.
Date: January 21, 2025By:/s/ Terry Rosen, Ph. D.
Terry Rosen, Ph.D.
Chief Executive Officer
(Principal Executive Officer)

v3.24.4
Cover
Jan. 16, 2025
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jan. 16, 2025
Entity Registrant Name Arcus Biosciences, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-38419
Entity Tax Identification Number 47-3898435
Entity Address, Address Line One 3928 Point Eden Way
Entity Address, City or Town Hayward
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94545
City Area Code 510
Local Phone Number 694-6200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, Par Value $0.0001 Per Share
Trading Symbol RCUS
Security Exchange Name NYSE
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001724521
Arcus Biosciences (NYSE:RCUS)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Arcus Biosciences Charts.
Arcus Biosciences (NYSE:RCUS)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Arcus Biosciences Charts.